| Name | Title | Contact Details |
|---|
Clearsultings innovative problem solving and proven technology workflows help finance leaders embrace digital to become better business partners. Acting as a link across your business, we connect your vision with the processes, technology, and systems that yield success. We offer enterprise performance management, digital reporting, finance effectiveness, financial close, risk advisory, and treasury services that take a digital-minded approach to push your business further. Marketplace awards and recognition: • Certified - Great Places to Work (2023, 2022) • Inc. 5000 "Fastest-Growing Companies" - Inc. (2022, 2021, 2020) • #1 "Best Small Firms to Work For" - Consulting Magazine (2019) • "Seven Small Jewels" - Consulting Magazine (2019, 2018) • Top 25 "Best Consulting Firms" - Vault (2019)
gm3 is the leading web3-native professional services firm. We are dedicated to being the trusted partner of choice for companies and investors looking to navigate the exciting world of web3. Our mission is to provide expert consulting services that empower our clients to unlock the full potential of this transformative technology. gm3 Ventures connects Founders & Investors. For aspiring entrepreneurs, we offer a comprehensive range of financing services tailored to your specific needs. For investors, we provide access to diversified investment opportunities in the web3 ecosystem. With our rigorous due diligence process and curated network, we ensure quality deal flow. gm3 Research specializes in high-end, commissioned research and whitepaper curation across the web3, decentralized finance and technology spaces. Our commitment to excellence is led by Crypto Punk and Harvard University PhD, Dr. Michael Frisch. Together with our team of field experts, we illuminate the path to informed decision-making in the dynamic landscape of web3. gm3 Advisory provides tailored advice and strategic guidance to unlock the potential of web3 for both traditional companies exploring the space and web3-native companies looking to structure and scale their businesses. gm3 Curation offers luxury concierge services across physical art, digital art and high-end fashion. Our creative agency partnership has curated collections for some of the biggest high-end fashion brands in the world. The name gm3 stems from the ubiquitous gm (good morning) greeting that prevails in the decentralized finance & technology spaces. The number 3 represents the last digit in the term web3, which represents the 3rd major evolution of the internet.
AirBoss of America Corp. is a leading developer and manufacturer of advanced custom rubber compounds and finished rubber products. Founded in 1989 and headquartered in Newmarket, Ontario, Canada, the company operates multiple facilities in Canada and the United States. Originally known as IATCO Industries Inc., AirBoss has grown from manufacturing segmented tires to providing innovative solutions in industrial rubber products, personal protective equipment (PPE), and survivability solutions. The company offers a diverse range of products across various industries. This includes rubber compounds for automotive, heavy industry, and construction, as well as PPE for military, law enforcement, and healthcare professionals. AirBoss also develops survivability solutions, such as rapid deployment negative pressure isolation shelters. With a focus on quality and innovation, AirBoss serves customers in automotive, healthcare, defense, and industrial sectors, ensuring safety and reliability in their products. The company operates through several subsidiaries, enhancing its capabilities in rubber compounding and defense-related solutions.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.